NDAORALTABLET
Approved
Jul 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
TRIMETHOPRIM (trimethoprim) by Dr. Reddy's Laboratories is dihydrofolate reductase inhibitors [moa]. Approved for pneumocystis jiroveci pneumonia, hiv infection, urinary tract infection and 1 more indications. First approved in 1982.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Trimethoprim is a dihydrofolate reductase inhibitor antibacterial approved in 1982 for oral tablet administration. It treats a broad spectrum of infections including urinary tract infections, Pneumocystis jirovecii pneumonia, tuberculosis, and bacterial infections through inhibition of bacterial folate synthesis. The drug has been repurposed for multiple indications including HIV-related opportunistic infections and non-tuberculous mycobacterial disease.
$9KPart D
LOE ApproachingMinimal Part D spending and claim volume indicate a mature, niche product with limited commercial momentum and likely a small dedicated brand team.
Mechanism of Action
Dihydrofolate Reductase Inhibitors
Pharmacologic Class:
Dihydrofolate Reductase Inhibitor Antibacterial
Indications (4)
Worked on TRIMETHOPRIM at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.